Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Tae Wan Kim, Hong Joo Kim, Chang Uk Chon, Hyun Sun Won, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol. 2012;18(2):203-212.   Published online 2012 Jun 26     DOI:
Citations to this article as recorded by Crossref logo
Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation
He-Yun Cheng, Hsiu C. Lin, Hsiu L. Lin, Yow S. Uang, Joseph J. Keller, Li H. Wang
Frontiers in Pharmacology.2022;[Epub]     CrossRef
Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki
Journal of Hepatocellular Carcinoma.2022; Volume 9: 1279.     CrossRef
Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy
Pei-Chang Lee, Yu-Ju Chen, Yueh-Ching Chou, Kuei-Chuan Lee, Ping-Hsien Chen, Wei-Yu Kao, Yi-Hsiang Huang, Teh-Ia Huo, Han-Chieh Lin, Ming-Chih Hou, Fa-Yauh Lee, Jaw-Ching Wu, Chien-Wei Su
European Journal of Gastroenterology & Hepatology.2020; 32(3): 365.     CrossRef
Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis
Tzu-Hao Li, Yu-Lien Tsai, Chien-Fu Hsu, Chih-Wei Liu, Chia-Chang Huang, Ying-Ying Yang, Hung-Cheng Tsai, Shiang-Fen Huang, Yun-Cheng Hsieh, Hsuan-Miao Liu, Tzung-Yan Lee, Ming-Chih Hou, Chang-Youh Tsai, Han-Chieh Lin
Gastroenterology Research and Practice.2020; 2020: 1.     CrossRef
Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center
Nuretdin Suna, Diğdem Özer Etik, Serkan Öcal, Haldun Selçuk
Experimental and Clinical Transplantation.2019; 17(5): 632.     CrossRef
Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the UK Clinical Practice Research Datalink
Katrina Wilcox Hagberg, Vikrant V. Sahasrabuddhe, Katherine A. McGlynn, Susan S. Jick
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2016; 36(2): 187.     CrossRef
The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis
Iván Herrera, Sonia Pascual, Pedro Zapater, Fernando Carnicer, Pablo Bellot, José María Palazón
European Journal of Gastroenterology & Hepatology.2016; 28(10): 1194.     CrossRef
Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials
Maja Thiele, Agustín Albillos, Rozeta Abazi, Reiner Wiest, Lise L. Gluud, Aleksander Krag
Liver International.2015; 35(8): 2009.     CrossRef
Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law
Gerond Lake-Bakaar, Muneeb Ahmed, Amy Evenson, Alan Bonder, Salomao Faintuch, Vinay Sundaram
Liver Cancer.2014; 3(3-4): 428.     CrossRef
Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?
Maja Thiele, Reiner Wiest, Lise Lotte Gluud, Agustín Albillos, Aleksander Krag
Medical Hypotheses.2013; 81(5): 871.     CrossRef